107 related articles for article (PubMed ID: 14669296)
21. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
[TBL] [Abstract][Full Text] [Related]
22. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
[TBL] [Abstract][Full Text] [Related]
23. A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients.
Shiozawa S; Chihara K; Shiozawa K; Fujita T; Ikegami H; Koyama S; Kurimoto M
Clin Exp Immunol; 1986 Oct; 66(1):77-87. PubMed ID: 3802576
[TBL] [Abstract][Full Text] [Related]
24. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues.
Navarro S; Colamonici OR; Llombart-Bosch A
Mod Pathol; 1996 Feb; 9(2):150-6. PubMed ID: 8657722
[TBL] [Abstract][Full Text] [Related]
26. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
Wozniak MB; Tracey L; Ortiz-Romero PL; Montes S; Alvarez M; Fraga J; Fernández Herrera J; Vidal S; Rodriguez-Peralto JL; Piris MA; Villuendas Deceased R
Br J Dermatol; 2009 Jan; 160(1):92-102. PubMed ID: 18945306
[TBL] [Abstract][Full Text] [Related]
27. Expression of IFN-gamma and its receptor alpha in the peripheral blood of patients with chronic hepatitis C.
Zhang P; Chen Z; Chen F; Li MW; Fan J; Zhou HM; Liu JH; Huang Z
Chin Med J (Engl); 2004 Jan; 117(1):79-82. PubMed ID: 14733779
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era.
Kai F; Takayama T; Sugiyama T; Furuse H; Mugiya S; Ozono S
Jpn J Clin Oncol; 2009 May; 39(5):310-4. PubMed ID: 19363055
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.
Esuvaranathan K; Chiong E; Thamboo TP; Chan YH; Kamaraj R; Mahendran R; Teh M
Cancer; 2007 Mar; 109(6):1097-105. PubMed ID: 17311305
[TBL] [Abstract][Full Text] [Related]
30. Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients.
Shiba M; Nonomura N; Nakai Y; Nakayama M; Takayama H; Inoue H; Tsujimura A; Nishimura K; Okuyama A
Int J Urol; 2009 Apr; 16(4):356-9. PubMed ID: 19302507
[TBL] [Abstract][Full Text] [Related]
31. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
[TBL] [Abstract][Full Text] [Related]
32. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
33. Hematological malignancies are associated with a lower interferon-a blocking activity than solid tumors.
Karmaniolas K; Dalamaga M; Liatis S; Kaskara A; Rigopoulos A; Migdalis IN
Res Commun Mol Pathol Pharmacol; 2005; 117-118():65-75. PubMed ID: 18426079
[TBL] [Abstract][Full Text] [Related]
34. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behçet's disease.
Akman A; Sallakci N; Coskun M; Bacanli A; Yavuzer U; Alpsoy E; Yegin O
Br J Dermatol; 2006 Aug; 155(2):350-6. PubMed ID: 16882174
[TBL] [Abstract][Full Text] [Related]
35. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
36. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells.
Vitale G; van Koetsveld PM; de Herder WW; van der Wansem K; Janssen JA; Colao A; Lombardi G; Lamberts SW; Hofland LJ
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E559-66. PubMed ID: 19141687
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
38. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
[TBL] [Abstract][Full Text] [Related]
39. [Clinical effects of human fibroblast interferon in advanced gynecological cancers].
Kanazawa K; Honma S; Yuzawa H; Takeuchi S
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1276-83. PubMed ID: 6732254
[TBL] [Abstract][Full Text] [Related]
40. Clinical parameters to predict response to interferon in relapsing multiple sclerosis.
Fromont A; Debouverie M; Le Teuff G; Quantin C; Binquet C; Moreau T
Neuroepidemiology; 2008; 31(3):150-6. PubMed ID: 18716412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
